Дендритно-клеточные вакцины при раке легкого: современное состояние и перспективы развития. Обзор литературы

Представлен обзор литературы, посвященной использованию дендритно-клеточных вакцин при раке легкого. Обзор подготовлен по результатам анализа отечественных и зарубежных работ, представленных в электронных базах данных научной медицинской литературы PubMed, eLIBRARY. В анализ включали публикации, характеризующие современные возможности лабораторных, инструментальных и молекулярно-генетических методов получения и использования дендритно-клеточных вакцин при раке легкого.
Цель работы – осветить результаты международных и отечественных исследований получения, скрининга использования дендритно-клеточных вакцин, а также стратегии иммунотерапии при раке легкого.

1. Bray F., Ferlay J., Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018;68(6):394–424. DOI: 10.3322/caac.21492

2. Siegel R.L., Miller K.D., Jemal A. Cancer statistics 2018. CA Cancer J Clin 2018;68(1):7–30. DOI: 10.3322/caac.21442

3. Абдурахманов Б.А., Авизова З.К. Смертность от рака легкого из-за задержки лечения: обзор литературы. Онкология и радиология Казахстана 2021;2(60):36–8. DOI: 10.52532/2521-6414-2021-2-60-36-38

4. Ларина В.Н., Вартанян Е.А., Самородская И.В. Анализ структуры смертности от злокачественных новообразований в Москве в 2019, 2020, 2021 гг. Онкология. Журнал им. П.А. Герцена 2023;12(4):35–41. DOI: 10.17116/onkolog20231204135

5. Злокачественные новообразования в России в 2023 году (заболеваемость и смертность). Под ред. А.Д. Каприна, В.В. Старинского, А.О. Шахзадовой. М.: МНИОИ им. П.А. Герцена – филиал ФГБУ «НМИЦ радиологии» Минздрава России, 2024. 276 с. 5.

6. Borghaei H., Paz-Ares L., Horn L. et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med 2015;373(17):1627–39. DOI: 10.1056/NEJMoa1507643

7. Reck M., Rodríguez-Abreu D., Robinson A.G. et al. Pembrolizumab versus chemotherapy for PD-L1-positive nonsmall-cell lung cancer. N Engl J Med 2016;375(19):1823–33. DOI: 10.1056/NEJMoa1606774

8. Gandhi L., Rodríguez-Abreu D., Gadgeel S. et al. Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer. N Engl J Med 2018;378(22):2078–92. DOI: 10.1056/NEJMoa1801005

9. Brahmer J., Reckamp K.L., Baas P. et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med 2015;373(2):123–35. DOI: 10.1056/NEJMoa1504627

10. Muenst S., Laubli H., Soysal S.D. et al. The immune system and cancer evasion strategies: therapeutic concepts. J Intern Med 2016;279(6):541–62. DOI: 10.1111/joim.12470

11. O’Donnell J.S., Teng M.W.L., Smyth M.J. Cancer immunoediting and resistance to T cell-based immunotherapy. Nat Rev Clin Oncol 2019;16(3):151–67. DOI: 10.1038/s41571-018-0142-8

12. Ruiz-Cordero R., Devine W.P. Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin 2020;13(1):17–33. DOI: 10.1016/j.path.2019.11.002

13. Vermaelen K. Vaccine strategies to improve anti-cancer cellular immune responses. Front Immunol 2019;10:8. DOI: 10.3389/fimmu.2019.00008

14. Kalinski P., Muthuswamy R., Urban J. Dendritic cells in cancer immunotherapy: vaccines and combination immunotherapies. Expert Rev Vaccines 2013;12(3):285–95. DOI: 10.1586/erv.13.22

15. Bol K.F., Schreibelt G., Rabold K. et al. The clinical application of cancer immunotherapy based on naturally circulating dendritic cells. J Immunother Cancer 2019;7(1):109. DOI: 10.1186/s40425-019-0580-6.

16. Gardner A., de Mingo Pulido Á., Ruffell B. Dendritic cells and their role in immunotherapy. Front Immunol 2020;11:924. DOI: 10.3389/fimmu.2020.00924

17. OʼNeill L.A., Kishton R.J., Rathmell J. A guide to immunometabolism for immunologists. Nat Rev Immunol 2016;16(9):553–65. DOI: 10.1038/nri.2016.70

18. Brombacher E.C., Patente T.A., Quik M., Everts B. Characterization of dendritic cell metabolism by flow cytometry. In: Dendritic cells. Methods in molecular biology. Ed. by V. Sisirak. Vol. 2618. NY: Humana, New York, 2023. DOI: 10.1007/978-1-0716-2938-3_16

19. Gardner A., Ruffell B. Dendritic cells and cancer immunity. Trends Immunol 2016;37(12):855–65. DOI: 10.1016/j.it.2016.09.006

20. Veglia F., Gabrilovich D.I. Dendritic cells in cancer: the role revisited. Curr Opin Immunol 2017;45:43–51. DOI: 10.1016/j.coi.2017.01.002

21. Filin I.Y., Kitaeva K.V., Rutland C.S. et al. Recent advances in experimental dendritic cell vaccines for cancer. Front Oncol 2021;11:730824. DOI: 10.3389/fonc.2021.730824

22. Collin M., Bigley V. Human dendritic cell subsets: an update. Immunology 2018;154(1):3–20. DOI: 10.1111/imm.12888

23. Heger L., Hofer T.P., Bigley V. et al. Subsets of CD1c+ DCs: dendritic cell versus monocyte lineage. Front Immunol 2020;11:559166. DOI: 10.3389/fimmu.2020.559166

24. Leader A.M., Grout J.A., Maier B.B. et al. Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification. Cancer Cell 2021;39(12):1594–609.e1512. DOI: 10.1016/j.ccell.2021.10.009

25. Bourdely P., Anselmi G., Vaivode K. et al. Transcriptional and functional analysis of CD1c+ human dendritic cells identifies a CD163+ subset priming CD8+CD103+ T cells. Immunity 2020;53(2):335–52.e338. DOI: 10.1016/j.immuni.2020.06.002

26. Marceaux C., Weeden C.E., Gordon C.L., Asselin-Labat M.L. Holding our breath: the promise of tissue-resident memory T cells in lung cancer. Transl Lung Cancer Res 2021;10(6):2819–29. DOI: 10.21037/tlcr-20-819

27. Stevens D., Ingels J., Van Lint S. et al. Dendritic cell-based immunotherapy in lung cancer. Front Immunol 2021;11:620374. DOI: 10.3389/fimmu.2020.620374

28. Cook P.C., MacDonald A.S. Dendritic cells in lung immunopathology. Semin Immunopathol 2016;38(4):449–60. DOI: 10.1007/s00281-016-0571-3

29. Kim N., Kim H.K., Lee K. et al. Single-cell RNA sequencing demonstrates the molecular and cellular reprogramming of metastatic lung adenocarcinoma. Nat Commun 2020;11(1):2285. DOI: 10.1038/s41467-020-16164-1

30. Sadeghzadeh M., Bornehdeli S., Mohahammadrezakhani H. et al. Dendritic cell therapy in cancer treatment; the state-of-the-art. Life Sci 2020;254:117580. DOI: 10.1016/j.lfs.2020.117580

31. Wang J.B., Huang X., Li F.R. Impaired dendritic cell functions in lung cancer: a review of recent advances and future perspectives. Cancer Commun (Lond) 2019;39(1):43. DOI: 10.1186/s40880-019-0387-3

32. Schneider T., Hoffmann H., Dienemann H. et al. Non-small cell lung cancer induces an immunosuppressive phenotype of dendritic cells in tumor microenvironment by upregulating B7-H3. J Thorac Oncol 2011;6(7):1162–8. DOI: 10.1097/JTO.0b013e31821c421d

33. Topalian S.L., Taube J.M., Pardoll D.M. Neoadjuvant checkpoint blockade for cancer immunotherapy. Science 2020;367(6477):eaax0182. DOI: 10.1126/science.aax0182.

34. Jiang T., Chen X., Zhou W. et al. Immunotherapy with dendritic cells modified with tumor-associated antigen gene demonstrates enhanced antitumor effect against lung cancer. Transl Oncol 2017;10(2):132–41. DOI: 10.1016/j.tranon.2016.12.002

35. Shuo W., Yuntian D., Huan P. et al. Progress in the treatment of non-small cell lung cancer with immune checkpoint inhibitors. Med J Peking Union Medical College Hospital 2023;14(2):409–15.

36. Melero I., Castanon E., Alvarez M. et al. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat Rev Clin Oncol 2021;18(9):558–76. DOI: 10.1038/s41571-021-00507-y

37. Tao Li., Kan Zh., Wenyu Ya. et al. Clinical application of immune checkpoint inhibitors CTLA-4 in solid tumors. Med J Peking Union Medical College Hospital 2023;14(3):652–9. DOI: 10.12290/xhyxzz.2022-0617

38. Liyuan D., Yuankai Sh., Xiaohong H. Advances in dynamic monitoring of immune checkpoint inhibitors as the prognostic markers for advanced non-small cell lung cancer. Med J Peking Union Medical College Hospital 2022;13(2):287–95. DOI: 10.12290/xhyxzz.2021-0608

39. Mastelic-Gavillet B., Balint K., Boudousquie C. et al. Personalized dendritic cell vaccines-recent breakthroughs and encouraging clinical results. Front Immunol 2019;10:766. DOI: 10.3389/fimmu.2019.00766

40. Lee K.W., Yam J.W.P., Mao X. Dendritic cell vaccines: a shift from conventional approach to new generations. Cells 2023;12(17):2147. DOI: 10.3390/cells12172147

41. Takahashi H., Shimodaira S., Ogasawara M. et al. Lung adenocarcinoma may be a more susceptive subtype to a dendritic cell-based cancer vaccine than other subtypes of non-small cell lung cancers: a multicenter retrospective analysis. Cancer Immunol Immunother 2016;65(9):1099–111. DOI: 10.1007/s00262-016-1872-z

42. Ge C., Li R., Song H. et al. Phase I clinical trial of a novel autologous modified-DC vaccine in patients with resected NSCLC. BMC Cancer 2017;17(1):884. DOI: 10.1186/s12885-017-3859-3

43. Sanchez-Paulete A.R., Cueto F.J., Martinez-Lopez M. et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 2016;6(1):71–9. DOI: 10.1158/2159-8290.CD-15-0510

44. Hammerich L., Marron T.U., Upadhyay R. et al. Systemic clinical tumor regressions and potentiation of PD1 blockade with in situ vaccination. Nat Med 2019;25(5):814–24. DOI: 10.1038/s41591-019-0410-x

45. Ingels J., De Cock L., Stevens D. et al. Neoantigen-targeted dendritic cell vaccination in lung cancer patients induces long-lived T cells exhibiting the full differentiation spectrum. Cell Rep Med 2024;5(5):101516. DOI: 10.1016/j.xcrm.2024.101516

46. Huang J., Reckamp K.L. Immunotherapy in advanced non-small cell lung cancer. Semin Respir Crit Care Med 2020;41(3):400–8. DOI: 10.1055/s-0040-1710077

47. Punekar S.R., Shum E., Grello C.M. et al. Immunotherapy in non-small cell lung cancer: past, present, and future directions. Front Oncol 2022;12:877594. DOI: 10.3389/fonc.2022.877594

48. Desai A., Peters S. Immunotherapy-based combinations in metastatic NSCLC. Cancer Treat Rev 2023;116:102545. DOI: 10.1016/j.ctrv.2023.102545

49. Харагезов Д.А., Антонян А.А., Златник Е.Ю. и др. Роль опухолевых стволовых клеток и иммунного микроокружения в патогенезе рака легкого: механизмы взаимодействия и перспективы исследований. Южно-Российский онкологический журнал 2024;5(4):58–70. DOI: 10.37748/2686-9039-2024-5-4-7

50. De Oliveira J.B., Silva S.B., Fernandes I.L. et al. Dendritic cell-based immunotherapy in non-small cell lung cancer: a comprehensive critical review. Front Immunol 2024; 15:1376704. DOI: 10.3389/fimmu.2024.1376704

51. Laureano R.S., Sprooten J., Vanmeerbeerk I. et al. Trial watch: dendritic cell (DC)-based immunotherapy for cancer. Oncoimmunology 2022;11(1):2096363. DOI: 10.1080/2162402X.2022.2096363

52. Kumar C., Kohli S., Bapsy P.P. et al. Immune modulation by dendritic-cell-based cancer vaccines. J Biosci 2017;42(1):161–73. DOI: 10.1007/s12038-017-9665-x